Skip to content

Study · Randomized controlled trial · n = 96 · 2003

5 results

Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).

Fogelman I, Blake GM, Blamey R, Palmer M, Sauerbrei W, Schumacher M, Serin D, Stewart A, Wilpshaar W

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA3 Oct 2003Cited by 77 (Europe PMC)

PMID14530912 (opens in a new tab)DOI10.1007/s00198-003-1508-y (opens in a new tab)PepBankPUB-14530912
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In women with node-positive early breast cancer, lumbar spine bone density fell by 10.5% with goserelin versus 6.5% with CMF at 2 years (P=0.0005).

    In plain wordsIn women with early breast cancer, spine bone density fell more with goserelin than CMF after 2 years.

    Peptide
    Goserelin
    Outcome
    DecreaseLumbar spine bone mineral density at 2 years
    Study

    n = 96

    Comparator
    CMF chemotherapy
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.6 mg every 28 days · 2 yearsAs given in this study (human).

    Measurements

    Lumbar spine BMD change
    −10.5%
    goserelin
    Lumbar spine BMD change
    −6.5%
    CMF

    Source sentences

    Summary
    At the end of the 2-year goserelin-treatment period, mean BMD losses for goserelin-treated and CMF-treated patients were -10.5% and -6.5% ( P=0.0005) for lumbar spine and -6.4% and -4.5% ( P=0.04) for femoral neck, respectively.
    2 context sentences
    Summary · context
    Patients ( n=1640) were randomized to goserelin (3.6 mg every 28 days for 2 years) or CMF (sixx28-day cycles) treatment.
    Summary · context
    In a protocoled sub-study involving 96 patients from eight centers (goserelin: n=53; CMF: n=43), lumbar spine (L2-L4) and femoral neck BMD were assessed by dual X-ray absorptiometry at baseline and then annually for 3 years.
  2. 02HumanRandomized controlled trialSafety outcome

    In women with node-positive early breast cancer, femoral neck bone density fell by 6.4% with goserelin versus 4.5% with CMF at 2 years (P=0.04).

    In plain wordsIn women with early breast cancer, hip bone density fell more with goserelin than CMF after 2 years.

    Peptide
    Goserelin
    Outcome
    DecreaseFemoral neck bone mineral density at 2 years
    Study

    n = 96

    Comparator
    CMF chemotherapy
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.6 mg every 28 days · 2 yearsAs given in this study (human).

    Measurements

    Femoral neck BMD change
    −6.4%
    goserelin
    Femoral neck BMD change
    −4.5%
    CMF

    Source sentences

    Summary
    At the end of the 2-year goserelin-treatment period, mean BMD losses for goserelin-treated and CMF-treated patients were -10.5% and -6.5% ( P=0.0005) for lumbar spine and -6.4% and -4.5% ( P=0.04) for femoral neck, respectively.
    2 context sentences
    Summary · context
    Patients ( n=1640) were randomized to goserelin (3.6 mg every 28 days for 2 years) or CMF (sixx28-day cycles) treatment.
    Summary · context
    In a protocoled sub-study involving 96 patients from eight centers (goserelin: n=53; CMF: n=43), lumbar spine (L2-L4) and femoral neck BMD were assessed by dual X-ray absorptiometry at baseline and then annually for 3 years.
  3. 03HumanRandomized controlled trialSafety outcome

    In women with early breast cancer, spine bone mineral density did not differ significantly between goserelin and CMF at 3 years.

    In plain wordsIn women with early breast cancer, spine bone density did not differ significantly between goserelin and CMF at 3 years.

    Peptide
    Goserelin
    Outcome
    No significant changeSpine bone mineral density at 3 years
    Study

    n = 96

    Comparator
    CMF chemotherapy
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.6 mg every 28 days · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    No significant differences in BMD were observed between groups at the 3-year assessment of the spine or femoral neck.
    2 context sentences
    Summary · context
    Patients ( n=1640) were randomized to goserelin (3.6 mg every 28 days for 2 years) or CMF (sixx28-day cycles) treatment.
    Summary · context
    In a protocoled sub-study involving 96 patients from eight centers (goserelin: n=53; CMF: n=43), lumbar spine (L2-L4) and femoral neck BMD were assessed by dual X-ray absorptiometry at baseline and then annually for 3 years.
  4. 04HumanRandomized controlled trialSafety outcome

    In women with early breast cancer, femoral neck bone mineral density did not differ significantly between goserelin and CMF at 3 years.

    In plain wordsIn women with early breast cancer, hip bone density did not differ significantly between goserelin and CMF at 3 years.

    Peptide
    Goserelin
    Outcome
    No significant changeFemoral neck bone mineral density at 3 years
    Study

    n = 96

    Comparator
    CMF chemotherapy
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.6 mg every 28 days · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    No significant differences in BMD were observed between groups at the 3-year assessment of the spine or femoral neck.
    2 context sentences
    Summary · context
    Patients ( n=1640) were randomized to goserelin (3.6 mg every 28 days for 2 years) or CMF (sixx28-day cycles) treatment.
    Summary · context
    In a protocoled sub-study involving 96 patients from eight centers (goserelin: n=53; CMF: n=43), lumbar spine (L2-L4) and femoral neck BMD were assessed by dual X-ray absorptiometry at baseline and then annually for 3 years.
  5. 05HumanNon-randomized trialSafety outcome

    In women with early breast cancer previously treated with goserelin, bone mineral density partially recovered at 3 years.

    In plain wordsIn women with early breast cancer previously given goserelin, bone density partially recovered at 3 years.

    Peptide
    Goserelin
    Outcome
    IncreaseBone mineral density recovery at 3 years
    Study

    n = 53

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.6 mg every 28 days · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    At 3 years, partial recovery of BMD was observed in goserelin recipients.
    2 context sentences
    Summary · context
    Patients ( n=1640) were randomized to goserelin (3.6 mg every 28 days for 2 years) or CMF (sixx28-day cycles) treatment.
    Summary · context
    In a protocoled sub-study involving 96 patients from eight centers (goserelin: n=53; CMF: n=43), lumbar spine (L2-L4) and femoral neck BMD were assessed by dual X-ray absorptiometry at baseline and then annually for 3 years.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.